Inovio Pharmaceuticals(FRA) GBMB

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

Inovio Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$832.01K

Net Income (TTM)

-$135.12M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Feb 28, 2024

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Feb 28, 2024

GBMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to developing and commercializing DNA medicines. The company focuses on treating diseases related to human papillomavirus (HPV), various cancers, and infectious pathogens through its innovative DNA medicines platform.

Products and Services

DNA medicines targeting HPV-related diseases and cancers
Proprietary SynCon technology for optimized DNA sequences
CELLECTRA smart devices for efficient DNA delivery

Growth Outlook

Expanding clinical investigations for multiple cancer types and infectious diseases
Collaborations with major institutions enhance research capabilities
Potential market growth driven by increasing demand for innovative therapies

Financial Highlights

Q4 2023 revenue of 102,651, showing a steady demand for products
Trailing twelve months (TTM) net income reflects ongoing investment in R&D
Cash and short-term investments totaled 145,293,775, providing operational flexibility

Inovio Pharmaceuticals is positioned at the forefront of biotechnology, leveraging its proprietary technologies to address significant health challenges. The company's focus on DNA medicines offers a unique approach to treatment, particularly in the realm of HPV-related conditions and various cancers. With a robust pipeline and strategic partnerships, Inovio is well-equipped to navigate the evolving landscape of biotechnology. Recent financial data indicates a commitment to research and development, which is essential for long-term growth and innovation. The company's financial health, underscored by substantial cash reserves, supports its ongoing projects and potential market expansion.

AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

112

CEO

Jacqueline E. Shea, PhD

Website

www.inovio.com

Headquarters

Plymouth Meeting, PA 19462, US

GBMB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1005.80%

Return on Capital

-97.55%

Return on Assets

-136.52%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$832.01K

Operating Income

-$143.94M

EBITDA

-$147.81M

Operating Cash Flow

-$124.37M

Capital Expenditure

-$320.90K

Free Cash Flow

-$124.69M

Cash & ST Invst.

$145.29M

Total Debt

$30.21M

Inovio Pharmaceuticals Performance Analysis

Inovio Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 9,764,528	550.3%
2023	2023-12-31	USD 769,585	-92.1%
2024	2024-12-31	USD 201,311	-73.8%
2025	2025-12-31	USD 57,899	-71.2%

Inovio Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2023-03-31	-7.8%
Q2	2023-06-30	96.6%
Q3	2023-09-30	71.9%
Q4	2023-12-31	-73.6%

Inovio Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -13.39	-9.3%
2023	2023-12-31	USD -5.64	-57.9%
2024	2024-12-31	USD -3.65	-35.2%
2025	2025-12-31	USD -1.61	-56.0%

Inovio Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2023-03-31	27.3%
Q2	2023-06-30	18.8%
Q3	2023-09-30	N/A
Q4	2023-12-31	28.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2023YOY CHG

Revenue

$102.65K

-17.7%

Gross Profit

$102.65K

-17.7%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

184

N/A

Net Income

-$25.00M

+54.1%

EBITDA

-$26.08M

+52.0%

Quarterly Fundamentals

Name

Q4 2023YOY CHG

Total Cash

$145.29M

-42.6%

Total Debt

$30.21M

-5.8%

Accounts Receivable

$2.41M

-79.5%

Inventory

$5.39M

N/A

Long Term Debt

$11.03M

-62.3%

Short Term Debt

$19.18M

+583.9%

Return on Assets

-1.37%

N/A

Return on Invested Capital

-8.37%

N/A

Free Cash Flow

-$26.28M

+28.0%

Operating Cash Flow

-$26.28M

+27.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About GBMB

What is the current price of Inovio Pharmaceuticals?

Inovio Pharmaceuticals is trading at N/A per share.

What is the 52-week range for Inovio Pharmaceuticals?

Over the past 52 weeks, Inovio Pharmaceuticals has traded between N/A and N/A.

How much debt does Inovio Pharmaceuticals have?

As of the most recent reporting period, Inovio Pharmaceuticals reported total debt of $7.00M.

How much cash does Inovio Pharmaceuticals have on hand?

Inovio Pharmaceuticals reported $27.57M in cash and cash equivalents in its most recent financial results.

What is Inovio Pharmaceuticals’s dividend yield?

Inovio Pharmaceuticals does not currently have a dividend yield.

Inovio Pharmaceuticals(FRA) GBMB

Inovio Pharmaceuticals Financials at a Glance

GBMB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Inovio Pharmaceuticals

GBMB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Inovio Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GBMB

What is the current price of Inovio Pharmaceuticals?

What is the 52-week range for Inovio Pharmaceuticals?

How much debt does Inovio Pharmaceuticals have?

How much cash does Inovio Pharmaceuticals have on hand?

What is Inovio Pharmaceuticals’s dividend yield?

Premium Investing Services